LETTER TO THE EDITOR
Sustainable effect of ultra-low dose rituximab for mild-to-moderate pemphigus vulgaris: A case report
Yu-An Wang,
Yu-An Wang
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Search for more papers by this author Julia Yu-Yun Lee,
Julia Yu-Yun Lee
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Search for more papers by this author Chao-Chun Yang,
Corresponding Author
Chao-Chun Yang
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan
Correspondence
Chao-Chun Yang, Department of Dermatology, National Cheng Kung University Hospital, 138 Sheng-Li Road, North District, 704 Tainan, Taiwan.
Email: [email protected]
Search for more papers by this author
Yu-An Wang,
Yu-An Wang
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Search for more papers by this author Julia Yu-Yun Lee,
Julia Yu-Yun Lee
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Search for more papers by this author Chao-Chun Yang,
Corresponding Author
Chao-Chun Yang
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan
Correspondence
Chao-Chun Yang, Department of Dermatology, National Cheng Kung University Hospital, 138 Sheng-Li Road, North District, 704 Tainan, Taiwan.
Email: [email protected]
Search for more papers by this author
First published: 14 September 2021
No abstract is available for this article.
CONFLICT OF INTEREST
None declared.
REFERENCES
- 1Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol. 2016; 74: 746–53.
- 2Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 143–50.
- 3Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020; 182: 1111–9.
- 4Russo I, Miotto S, Saponeri A, Alaibac M. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. Expert Opin Biol Ther. 2020; 20: 673–8.
- 5Schoergenhofer C, Schwameis M, Firbas C, Bartko J, Derhaschnig U, Mader RM, et al. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. Sci Rep. 2018; 8: 124.
